China’s NMPA has issued Implementation Opinions that formally incorporate AI‑enabled regulatory functions into the statutory framework governing drug oversight. The document delineates a progressive restructuring of review, inspection, and post‑market supervision through algorithmic assessment tools and unified national data infrastructures. It further outlines a phased regulatory trajectory toward a fully integrated digital governance ecosystem by 2030 and 2035.
For market operators in China, the reform introduces elevated obligations concerning data integrity and traceability, structured submissions, and digital compliance controls. Regulatory determinations will increasingly rely on machine‑assisted analytics and predictive supervision, requiring enhanced end‑to‑end compliance readiness across pharmaceutical and medical‑device activities.